Insulin degludec: A significant advancement in ultralong-acting basal insulin

Diabetes Therapy

Volumn 4, Issue 2, 2013, Pages 167-173

  Kalra, Sanjay ^a  

^a Bharti Hospital and Bharti Research Institute of Diabetes and Endocrinology   (India)

Author keywords

Basal insulin; Diabetes; Insulin; Insulin analogs; Insulin degludec

Indexed keywords

HEMOGLOBIN A1C; INSULIN; INSULIN DEGLUDEC; INSULIN RECEPTOR; LONG ACTING INSULIN; SOMATOMEDIN C;

DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; EDITORIAL; FOOD AND DRUG ADMINISTRATION; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; MITOGENICITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL;

EID: 84899840963     PISSN: 18696953     EISSN: 18696961     Source Type: Journal    
DOI: 10.1007/s13300-013-0047-6     Document Type: Editorial

References (22)

1. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. Management of hyperglycaemia in type 2 diabetes: a patientcentered approach. Position statement of the American diabetes association (ADA) and the European Association for the study of diabetes (EASD). Diabetologia. 2012;55:1577-96.
2. Heise T, Nosek L, Ronn BB, Endahl L, Heinemann L, Kapitza C, et al. Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. Diabetes. 2004;53:1614-20.
3. Ashwell SG, Gebbie J, Home PD. Twice-daily compared with once-daily insulin glargine in people with Type 1 diabetes using meal-time insulin aspart. Diabet Med. 2006;23(8):879-86.
4. Karges B, Boehm BO, Karges W. Early hypoglycaemia after accidental intramuscular injection of insulin glargine. Diabet Med. 2005;22(10):1444-5.
5. Kalra S, Unnikrishnan AG, Baruah M, Kalra B. Degludec insulin: novel basal insulin. Indian J Endocr Metab. 2011;15:12-6.
6. Nicolucci A, Kovacs Burns K, Holt RIG, Comaschi M, Hermanns N, Ishii H, et al. Diabetes Attitudes, Wishes and Needs second study (DAWN2™): Cross-national benchmarking of diabetes-related psychosocial outcomes for people with diabetes. Diabet Med. 2013;30(7):767-77.
7. Kovacs Burns K, Nicolucci A, Holt RIG, Willaing I, Hermanns N, Kalra S, et al. Diabetes Attitudes, Wishes and Needs second study (DAWN2™): crossnational benchmarking indicators for family members living with people with diabetes. Diabet Med. 2013;30(7):778-88.
8. Kurzhals P, Heise T, Strauss HM, Bøttcher SG, Granhall C, Haahr H, Jonassen I. Multi-hexamer formation is the underlying mechanism behind the ultra-long glucose-lowering effect of insulin degludec. Diabetes. 2011;60(Suppl 1):LB12.
9. Nishimura E, Rensen AO, Falckhansen BO, Stidsen C, Olsen GS, Schaumlffer L, et al. Insulin degludec is a new generation ultra-long acting basal insulin designed to maintain full metabolic effect while minimizing mitogenic potential. American Diabetes Association (ADA) 70th Scientific Sessions: Abstract 1406-P.
10. Heise T, Hövelmann U, Nosek L, Bøttcher SG, Granhall C, Haahr H. Insulin degludec has a two-fold longer half-life and a more consistent pharmacokinetic profile than insulin glargine. Diabetes. 2011;60(Suppl 1):LB11.
11. Heise T, Hermanski L, Nosek L, Feldman A, Rasmussen S, Haahr H. Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes. Diabetes Obes Metab. 2012;14: 859-64.
12. Birkeland KI, Home PD, Wendisch U, Ratner RE, Johansen T, Endahl LA, et al. Insulin degludec in type 1 diabetes: randomized controlled trial of a new-generation ultra-long-acting insulin compared with insulin glargine. Diabetes Care. 2011;34: 661-5.
13. Heise T, Tack CJ, Cuddihy R, Davidson J, Gouet D, Liebl A, et al. A new-generation ultra-long-acting basal insulin with a bolus boost compared with insulin glargine in insulin-naïve people with type 2 diabetes: a randomized, controlled trial. Diabetes Care. 2011;34:669-74.
14. Zinman B, Prillis-Tsimikar A, Cariou B, Handelsman Y, Rodbard HW, Johansen T, et al. Insulin degludec versus glargine in insulin naive patients with type 2 diabetes: a randomized treat to target trial (BEGIN Once Long). Diabetes Care. 2012;35:2464-71.
15. Ratner RE, Gough SCL, Mathieu C, Del Prato S, Bode B, Mersebach H, et al. Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a pre-planned meta-analysis of phase 3 trials. Diabetes Obes Metab. 2013;15:175-84.
16. Mathieu C, Hollander P, Miranda-Palma B, Cooper J, Franek E, Russell-Jones D, et al. Efficacy and safety of insulin degludec in a flexible dosing regimen vs. insulin glargine in patients with type 1 diabetes (BEGIN: Flex T1): a 26-week randomized, treat-totarget trial with a 26-week extension. J Clin Endocrinol Metab. 2013;98(3):1154-62.
17. Rana A, Meneghini L, Atkin S, Bain SC, Gough S, Raz I, et al. Insulin degludec given in a flexible once-daily dosing regimen does not compromise efficacy or safety in type 2 diabetes. Prim Care Diabetes 2013;7(1):85-85.
18. Vaidya B, Pearce SHS. Management of hypothyroidism in adults. BMJ 2008;337.
19. Letterie GS, Chow GE. Effect of "missed" pills on oral contraceptive effectiveness. Obstet Gynecol. 1992;79:979-82.
20. Han TS, Bouloux PM. What is the optimal therapy for young males with hypogonadotropic hypogonadism? Clin Endocrinol. 2010;72:731-7.
21. FDA withholds insulin degludec approval; wants safety data. Available at: http://www.familypracticenews.com/news/diabetes-endocrinology-metabolism/single-article/fda-withholds-insulin-degludec-approval-wants-safety-data/db819817d382fd2744a59c04cad79c62.html. Accessed 27 Oct 2013.
22. Kalra S. Newer basal insulin analogues: degludec, detemir, glargine. J Pak Med Ass. 2013;63(11): 1442-4.